Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

What the trial testedas reported · 428 people · 2026

Not counted

−16%−21% to −11%

Bigger than 3 in 10 for cardiovascular events

As reported

HR 0.84, 95% CI 0.79–0.89

Not counted

−21%−27% to −14%

Bigger than 5 in 10 on the map

As reported

HR 0.79, 95% CI 0.73–0.86

the abstract, start to end

GLP-1 RAs reduced MACE by 16% (HR 0.84, 95% CI 0.79-0.89; high certainty) and the …

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

HR 0.840.79–0.89

Kidney outcomes

HR 0.790.73–0.86

GLP-1 receptor agonistsCardiovascular eventsKidney outcomes

1 / 3

2026

this paperpooled itcites it